Braveheart Bio, Inc. (BRVE): who owns it and who trades it
As of Nov 16, 2026, BRVE insiders reported 10 purchases worth $123M in the last 12 months. The largest buyer was Forbion Growth Opportunities Fund III Cooperatief U.A. (10% owner), with $64.8M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Braveheart Bio
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, BRVE insiders reported $123M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Marc L Andreessen +3 | 10% owner | Purchase | 1.10M | $18.00 | $19.8M | Form 4 |
| Aug 7, 2026 | Erez Chimovits | Director | Purchase | 1.67M | $18.00 | $30M | Form 4 |
| Aug 7, 2026 | Erez Chimovits | Director | Purchase | 273,333 | $18.00 | $4.9M | Form 4 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. +3 | 10% owner | Purchase | 1.68M | $18.00 | $30.2M | Form 4 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. +3 | 10% owner | Purchase | 1.92M | $18.00 | $34.6M | Form 4 |
| Aug 7, 2026 | James Paul Rickey | CFO | Purchase | 27,777 | $18.00 | $500K | Form 4 |
| Aug 7, 2026 | Christopher Viehbacher | Director | Purchase | 83,333 | $18.00 | $1.5M | Form 4 |
| Aug 7, 2026 | David I Malek | Director | Purchase | 4,166 | $18.00 | $75K | Form 4 |
| Aug 7, 2026 | Michele A. Anderson | Chief Development Office | Purchase | 1,111 | $18.00 | $20K | Form 4 |
| Aug 7, 2026 | David Charles Lubner | Director | Purchase | 55,555 | $18.00 | $1000K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% owner | $64.8M | – | Aug 7, 2026 |
| Erez Chimovits | Director, 10% owner | $34.9M | – | Aug 7, 2026 |
| Marc L Andreessen | 10% owner | $19.8M | – | Aug 7, 2026 |
| Christopher Viehbacher | Director | $1.5M | – | Aug 7, 2026 |
| David Charles Lubner | Director | $1000K | – | Aug 7, 2026 |
| James Paul Rickey | Chief Financial Officer | $500K | – | Aug 7, 2026 |
| David I Malek | Director | $75K | – | Aug 7, 2026 |
| Michele A. Anderson | Chief Development Officer | $20K | – | Aug 7, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BRVE short interest
Moderate short interest. 5.7% of BRVE shares are sold short: about 1 share in 17. Over the last 6 reports the number of shares short went up 508%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.15M BRVE shares were sold short, 5.7% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 262,573 shares, buying them all back would take about 19.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.15M | 5.72% | +5% | 262,573 | 19.6 |
| Oct 15, 2026 | 4.91M | 5.45% | +19% | 417,079 | 11.8 |
| Sep 30, 2026 | 4.13M | 4.59% | +68% | 809,950 | 5.1 |
| Sep 15, 2026 | 2.46M | 2.73% | +76% | 328,415 | 7.5 |
| Aug 31, 2026 | 1.40M | – | +65% | 249,992 | 5.6 |
| Aug 14, 2026 | 847,773 | – | – | 650,680 | 1.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Braveheart Bio company events
Braveheart Bio filed 4 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Nov 6, 2026AnnouncementShared information with investors. Filing
- Sep 8, 2026ResultsReleased financial results. Filing
- Aug 7, 2026RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold BRVE
2 of the 50 well-known investors we track reported holding BRVE in their latest 13F filing. The largest position is Israel Englander's, worth $2.3M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 115,035 | $2.3M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 51,600 | $1M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named BRVE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 13G | 12.9% |
| Nov 16, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 13G | 12.9% |
| Nov 9, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 13G | 8.2% |
| Nov 9, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 13G | 8.2% |
| Nov 5, 2026 | FMR LLC | 13G | 8.2% |
| Nov 5, 2026 | FMR LLC | 13G | 8.2% |
Questions about Braveheart Bio, Inc. (BRVE) stock
Are BRVE insiders buying or selling?
In the last 12 months, BRVE insiders reported 10 open-market purchases worth $123M and no sales. The latest trade was on Aug 7, 2026. See every trade.
What is the short interest in BRVE?
As of Oct 30, 2026, 5.15M BRVE shares were sold short, 5.7% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 262,573 shares, buying them all back would take about 19.6 trading days (days to cover). See the history.
Which famous investors hold BRVE?
2 of the 50 well-known investors we track reported BRVE in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $2.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.